KEY POINTS
- Arcadia Medicine has raised $9.25 million from high-profile investors including Sam Altman, Fred Ehrsam, and Dylan Field.
- AM-1002 is designed to be non-neurotoxic, with fewer cardiovascular and stimulant-related side effects than traditional MDMA.
- Sam Altman praised the project as 'an important step towards a potentially transformative psychiatric treatment'.
San Francisco biotech startup Arcadia Medicine has been cleared by the U.S. Food and Drug Administration (FDA) to begin human trials on what it calls a 'healthier' form of MDMA, the psychoactive compound better known as ecstasy.
